ArberDA, OraziA, HasserjianRP, et al.International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood, 2022; 140(11):1200-1228.
2.
BernardE, NannyaY, HasserjianRP, et al.Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med, 2020; 26(10):1549-1556.
3.
BernardE, TuechlerH, GreenbergPL, et al.Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid, 2022; 1(7):EVIDoa2200008.
4.
EsteyE, HasserjianRP, DöhnerH. Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal. Blood, 2022; 139(3):323-332.
5.
GreenbergPL, TuechlerH, SchanzJ, et al.Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 2012; 120(12):2454-2465.
6.
GrobT, Al HinaiASA, SandersMA, et al.Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2022; 139(15):2347-2354.
7.
HaaseD, StevensonKE, NeubergD, et al.TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019; 33(7):1747-1758.
8.
HaferlachT, NagataY, GrossmannV, et al.Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 2014; 28(2):241-247.
9.
KhouryJD, SolaryE, AblaO, et al.The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia, 2022; 36(7):1703-1719.
10.
Montalban-BravoG, Kanagal-ShamannaR, BentonCB, et al.Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv, 2020; 4(3):482-495.
11.
SallmanDA, KomrokjiR, VaupelC, et al.Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia, 2016; 30(3):666-673.
12.
StengelA, MeggendorferM, WalterW, et al.Interplay of TP53 allelic state, blast count, and’ complex karyotype on survival of patients with AML and MDS. Blood Adv, 2023; 7(18):5540-5548.
13.
WeinbergOK, SiddonA, MadanatYF, et al.TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv, 2022; 6(9):2847-2853.
14.
WongTN, RamsinghG, YoungAL, et al.Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015; 518(7540):552-555.
